ABP-671 is under clinical development by Jiangsu Atom Bioscience and Pharmaceutical and currently in Phase III for Gouty Arthritis (Gout). According to GlobalData, Phase III drugs for Gouty Arthritis (Gout) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how ABP-671’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABP-671 overview
ABP-671 is under development for the treatment of gout associated with hyperuricemia, chronic kidney disease and other hyperuricemia related diseases. It is a small molecule. The drug candidate is administered through oral route in the form of tablets. The drug candidate acts by targeting urate transporter 1 (URAT1).
Jiangsu Atom Bioscience and Pharmaceutical overview
Jiangsu Atom Bioscience and Pharmaceutical (Atom Bioscience) is a clinical stage biotechnology company. The company’s primary focus is on the development of best-in-class orally delivered small molecule drugs. These drugs are primarily designed for the treatment of inflammatory and metabolic diseases, including chronic gout, acute gout, and other conditions lacking effective treatments. It’s pipeline products include ABP-671, a URAT1 inhibitor for gout and hyperuricemia, ABP-431 and its structural analogues are firs-in-class anti-tumor drugs for the treatment of anti-gastric cancer, bowel cancer and triple-negative breast cancerand, ABP-745, intended for acute gout and other indications. Atom Bioscience is headquartered in Zhenjiang, Jiangsu, China.
For a complete picture of ABP-671’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
